Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
2.
Int J Clin Pharmacol Ther ; 40(6): 241-8, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12078937

ABSTRACT

OBJECTIVES: To conduct a post-marketing observational cohort study to assess the safety of mibefradil in the community, using Prescription-Event Monitoring (PEM). METHOD: Data were collected and analyzed on patients prescribed mibefradil by 1,996 General Practitioners (GPs) throughout England. Incidence densities were calculated for all reported events and selected events were followed-up by means of further questionnaires. RESULTS: The study was terminated early due to the voluntary withdrawal of mibefradil from the market because of potential drug interactions. A cohort of 3,085 patients was recruited, with a mean age of 64.5 years. The major indication for use was hypertension (55% of the cohort), the indication was not specified in 33% of patients. 80% of GPs expressing an opinion rated mibefradil as effective. The major reason for stopping was withdrawal from the market (2,342 patients). The commonest reported adverse events and reasons for stopping were malaise/lassitude, dizziness, edema and headache. Seven clinically serious reports of bradycardia/collapse were considered to be possible adverse drug reactions (ADRs) to mibefradil. All were in the elderly (> 65 years), 6 were considered to be a result of possible drug interactions. In total, 11 possible drug interactions occurred. Nine (8 reports of bradycardia and 1 of syncope) involved beta-blockers. Another, a report of collapse and severe bradycardia, occurred in a patient who had started a dihydropyridine calcium channel blocker within 24 hours of stopping mibefradil and the other was a report of palpitations and dyspnea in a patient on concomitant digoxin and sotalol. None of the 53 deaths occurring during the study was attributed to mibefradil. CONCLUSION: Mibefradil was only available on the UK market for 6 months before it was withdrawn from the market because of potential drug interactions. With respect to the reasons leading to its withdrawal, in this cohort of 3,085 patients, 11 possible drug interactions were detected (6 clinically significant) involving beta-blockers, a dihydropyridine calcium channel blocker and digoxin and/or sotalol. PEM can contribute to the understanding of ADRs caused by drug interactions occurring in real-life settings.


Subject(s)
Calcium Channel Blockers/adverse effects , Mibefradil/adverse effects , Adolescent , Adult , Aged , Aged, 80 and over , Angina Pectoris/drug therapy , Calcium Channel Blockers/therapeutic use , Dizziness/chemically induced , Drug Interactions , Drug and Narcotic Control , Edema/chemically induced , England , Fatigue/chemically induced , Female , Headache/chemically induced , Humans , Hypertension/drug therapy , Male , Mibefradil/therapeutic use , Middle Aged , Product Surveillance, Postmarketing/statistics & numerical data
3.
Rev Prat ; 52(5): 497-501, 2002 Mar 01.
Article in French | MEDLINE | ID: mdl-11949501

ABSTRACT

A drug's lifetime, whether it is short or long, may go through fantastic new developments. Such is the case with beta-blockers, some of which have long been prescribed in heart failure before having made the definite proof of their efficacy, provided they are used carefully regarding the Good Product Use. On the other hand, the development of mibefradil, a calcic antagonist prescribed in the treatment of hypertension and angina pectoris, was stopped abruptly a few weeks before its launching because of the occurrence of serious side effects in patients suffering from heart failure. These examples, which are taken amongst others, clearly show the difficulties encountered by pharmaceutical companies that are concerned in putting forward innovative, efficacious, and ... secure drugs.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Antihypertensive Agents/adverse effects , Drug Approval , Mibefradil/adverse effects , Drug Design , Drug Industry , Humans
4.
J Gend Specif Med ; 4(4): 13-7, 2001.
Article in English | MEDLINE | ID: mdl-11727466

ABSTRACT

Significant progress has been made in including women in clinical and drug evaluation trials. Nonetheless, for most drugs currently on the market, analysis of benefits by sex is not available. At least some of the adverse effects of newer drugs in women could be due to the lack of inclusion in studies from which therapeutic regimens were derived. The data currently available on potential sex differences in pharmacokinetics and pharmacodynamics are also limited by having been obtained from healthy subjects receiving only one medication in studies designed only to detect moderate-to-large (> 30-50%) differences between the sexes. The clinical environment is different: patients consume multiple medications, including over-the-counter medications as well as nutraceuticals and dietary supplements; patients are, on average, older than healthy volunteers or even patients enrolled in investigational studies; and patients are more likely to have multiple diseases. In addition, adequate numbers of women still have not been enrolled in clinical trials for the therapy of many common disorders. The prudent clinician will remember that every time a therapy is initiated for an individual patient, especially a female patient, it is a clinical trial and the outcome is uncertain.


Subject(s)
Clinical Trials as Topic/standards , National Institutes of Health (U.S.)/standards , Practice Guidelines as Topic , Women , Drug Evaluation, Preclinical/standards , Female , Humans , Mibefradil/adverse effects , Muscular Diseases/chemically induced , Pyridines/adverse effects , Sex Factors , United States , Women's Health
5.
Eur J Heart Fail ; 3(5): 627-30, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11595612

ABSTRACT

We report a case of symptomatic Torsades de pointes due to QTc prolongation by Mibefradil, which potentially explains unexpected deaths related to this drug. Multiple episodes of Torsades de pointes were documented in a 76-year-old woman with significant QTc prolongation of 0.53 s. After discontinuation of Mibefradil QTc intervals normalized and no further ventricular tachyarrythmias were observed. We conclude that Mibefradil can cause QTc prolongation and life threatening ventricular dysrhythmias.


Subject(s)
Calcium Channel Blockers/adverse effects , Mibefradil/adverse effects , Torsades de Pointes/chemically induced , Aged , Angina Pectoris/complications , Angina Pectoris/drug therapy , Calcium Channel Blockers/therapeutic use , Female , Humans , Hypertension/complications , Hypertension/drug therapy , Long QT Syndrome/complications , Mibefradil/therapeutic use , Tachycardia, Ventricular/chemically induced
6.
Drugs ; 59 Spec No 2: 17-24, 2000.
Article in French | MEDLINE | ID: mdl-11002855

ABSTRACT

The pharmacological management of heart failure has evolved during the last decade from therapies focused on improving haemodynamics to others that modulate neurohormonal systems which are activated in the setting of left ventricular dysfunction. Despite optimal inhibition of these systems with drugs such as ACE inhibitors, beta-blockers, digoxin and, most recently, spironolactone, the mortality rate remains unacceptably high. Calcium antagonists have long been investigated for use in a variety of cardiovascular diseases, including ischaemic heart disease, hypertension, and heart failure. However, concern has arisen with regard to the use of calcium antagonists in the treatment of left ventricular dysfunction--particularly those agents with negative inotropic activity. In addition, first generation dihydropyridines have also generated concern because of their profound vasodilatory effects and the fact that they have been shown to increase noradrenaline (norepinephrine) levels and neurohormonal activity. The third generation dihydropyridine calcium antagonists appear to be more promising therapies for heart failure, given their pharmacological properties of higher vascular selectivity and their minimal effects on neurohormonal activation. Several trials have been conducted with third generation dihydropyridines and additional trials are ongoing. A new class of calcium antagonists, which blocks the T-type calcium channel, was introduced in 1998. The prototype drug, mibefradil, was rigorously tested for use in heart failure in the Mortality Assessment in Congestive Heart Failure (MACH-1) trial. It was expected that calcium antagonists blocking the T-type calcium channel would be of benefit, because of their lack of negative inotropic effects and their ability to induce regression of hypertrophy. The results of the MACH-1 trial were disappointing, and the trial was prematurely discontinued as a result of excess mortality in the mibefradil arm. The purpose of this review is to examine the evidence-based pharmacotherapeutic strategies in the management of heart failure, and to discuss current and potential roles for calcium antagonists in the therapeutic regimen.


Subject(s)
Calcium Channel Blockers/pharmacology , Heart Failure/drug therapy , Mibefradil/pharmacology , Ventricular Dysfunction, Left/drug therapy , Calcium Channel Blockers/adverse effects , Calcium Channel Blockers/therapeutic use , Clinical Trials as Topic , Evidence-Based Medicine , Humans , Mibefradil/adverse effects , Mibefradil/therapeutic use
9.
Fundam Clin Pharmacol ; 14(1): 31-41, 2000.
Article in English | MEDLINE | ID: mdl-10681072

ABSTRACT

The objective of this study was to compare the antihypertensive efficacy and safety of losartan and mibefradil. 324 outpatients (57 +/- 9.2 years) with mild to moderate hypertension were randomly allocated in a double-blind fashion to receive 50 mg of losartan or mibefradil once daily p.o. for 6 weeks after 2 weeks of placebo run-in. Titration was then forced to 100 mg of losartan or mibefradil for an additional 6 weeks. Patients were assessed at baseline, 6 and 12 weeks. The primary efficacy variable was change in predose sitting diastolic (SDBP) and systolic (SSBP) blood pressure at 12 weeks. Secondary variables included change in mean 24-hour ambulatory blood pressure and comparison of safety and tolerability. Both treatments lowered SSBP and SDBP at 6 and 12 weeks (week 6: mibefradil -14/-9 mm Hg; losartan -12/-7 mm Hg) (P <0.001). The primary objective, a difference between treatments in reduction of SSBP and SDBP at week 12 could be demonstrated (mibefradil -22/-16 mm Hg; losartan -16/-10 mm Hg) (P=0.003 and P=0.001, respectively). Twenty-four-hour SBP and 24-hour DBP were reduced (P<0.001) within each treatment group at weeks 6 and 12. The secondary objective, a difference between treatments in reduction of 24-hour blood pressure at week 12 could be demonstrated (P<0.001). Twenty-four-hour heart rate was lowered in the mibefradil group at weeks 6 and 12 (P < 0.001). Responder rates at 6 and 12 weeks were 56.2% and 78.5% for mibefradil versus 56.1% and 55.3% for losartan (P = 0.001). Both treatments were equally well tolerated. This study demonstrates that 50 mg losartan is comparably effective to 50 mg mibefradil in the treatment of mild to moderate hypertension with 100 mg mibefradil being more potent than losartan.


Subject(s)
Antihypertensive Agents/therapeutic use , Calcium Channel Blockers/therapeutic use , Calcium Channels, T-Type/drug effects , Hypertension/drug therapy , Losartan/therapeutic use , Mibefradil/therapeutic use , Adolescent , Adult , Aged , Antihypertensive Agents/adverse effects , Blood Pressure/drug effects , Blood Pressure/physiology , Blood Pressure Monitoring, Ambulatory , Body Weight/physiology , Calcium Channel Blockers/adverse effects , Double-Blind Method , Electrocardiography/drug effects , Female , Humans , Hypertension/physiopathology , Losartan/adverse effects , Male , Mibefradil/adverse effects , Middle Aged
10.
Circulation ; 101(7): 758-64, 2000 Feb 22.
Article in English | MEDLINE | ID: mdl-10683349

ABSTRACT

BACKGROUND: Calcium antagonists have proved disappointing in long-term congestive heart failure (CHF) studies. Mibefradil, a new calcium antagonist that selectively blocks T-type calcium channels, has been shown to be an effective antihypertensive, antianginal, and anti-ischemic agent, and because of its different mechanism of action, it may be beneficial as adjunct therapy in CHF patients. METHODS AND RESULTS: This multicenter, randomized, double-blind study compared mibefradil with placebo as adjunct to usual therapy in 2590 CHF patients (NYHA class II to IV; left ventricular fraction <35%). The initial 50-mg daily dose of mibefradil was uptitrated to 100 mg after 1 month and continued up to 3 years. Patients were monitored at 1 week; 1, 2, and 3 months; and every 3 months thereafter. All-cause mortality, cardiovascular mortality, and cardiovascular morbidity/mortality were analyzed by use of the log-rank test (alpha=0.05). Substudies included exercise tolerance, plasma hormone and cytokines, echocardiography, and quality of life. Total mortality was similar between mibefradil- and placebo-treated patients (P=0.151). The 14% increased risk of mortality with mibefradil in the first 3 months was not statistically significant (P=0.093). Treatment groups had similar cardiovascular mortality (P=0.246), cardiovascular morbidity/mortality (P=0.783), and reasons for death or hospitalization. Patients comedicated with mibefradil and antiarrhythmics (class I or III), including amiodarone, had a significantly increased risk of death. Substudies demonstrated no significant differences between treatments. CONCLUSIONS: When used as adjunct therapy, mibefradil did not affect the usual outcome of CHF. The potential interaction with antiarrhythmic drugs, especially amiodarone, and drugs associated with torsade de pointes may have contributed to poor outcomes early in the study.


Subject(s)
Calcium Channel Blockers/therapeutic use , Heart Failure/drug therapy , Heart Failure/epidemiology , Mibefradil/therapeutic use , Aged , Calcium Channel Blockers/adverse effects , Calcium Channels, T-Type/drug effects , Double-Blind Method , Exercise Test , Female , Heart Failure/physiopathology , Humans , Male , Mibefradil/adverse effects , Middle Aged , Morbidity , Mortality , Physical Endurance/drug effects
11.
Eur J Clin Pharmacol ; 55(8): 559-65, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10541773

ABSTRACT

INTRODUCTION: Mibefradil was approved as a novel calcium antagonist in Switzerland in 1996. Following its launch as an antihypertensive and anti-anginal agent, there were reports about serious pharmacokinetic and pharmacodynamic interactions occurring with other drugs frequently administered to patients with cardiovascular diseases. Despite appropriate modifications of the prescribing information, such interactions continued to occur. The drug was finally withdrawn after a study in patients with congestive heart failure showed a trend to higher mortality with mibefradil. This increase in mortality could again be due to multiple interactions between mibefradil and other drugs. In retrospect, it can be concluded that several of the interactions, including the theoretical risk of severe toxicity in some patients, could have been and in fact were predicted on the basis of the data available before introduction to the market. Depending on the benefits, these problems would however not necessarily represent an unacceptable risk for a new active compound. RESULTS AND CONCLUSION: The most important points revealed by this analysis were: (1) when interpreting the results of interaction studies, it is important to consider not only the mean of the interaction effect but also the observed and the theoretically conceivable extreme effects in individual subjects and (2) a drug with a high interaction potential may represent a high risk even if an adequate warning is included in the product information. The need for specific pharmacokinetic and pharmacodynamic interaction studies with new drugs and the limitations of the pivotal clinical efficacy and safety studies during phase III in order to reveal such interactions are discussed.


Subject(s)
Calcium Channel Blockers/adverse effects , Calcium Channel Blockers/pharmacology , Mibefradil/adverse effects , Mibefradil/pharmacology , Drug Approval , Drug Interactions , Humans , Product Surveillance, Postmarketing , Switzerland
12.
Z Gastroenterol ; 37(10): 1025-8, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10549098

ABSTRACT

A 54-year-old male liver transplant patient received mibefradil, a novel T-type calcium channel blocker, as antihypertensive treatment while he was on tacrolimus. He subsequently developed dizziness and fatigue of gradual onset as well as shoulder muscle ache. In addition, reversible impairment of renal function occurred with an increase in creatinine and potassium levels. Monitoring of tacrolimus levels, which had been in the desired range (5-8 ng/ml) until recently, revealed an increase to toxic level of 54 ng/ml. After discontinuation of mibefradil, tacrolimus levels returned to the normal range and all symptoms and clinical changes were reversible. Mibefradil and tacrolimus both are metabolized through the cytochrome--P-450 pathway. We suspect that drug interaction due to competitive inhibition of tacrolimus metabolism by mibefradil was responsible for these toxic effects. Therefore, special caution is recommended when administering tacrolimus with other drugs that carry the potential for pharmakokinetic interaction.


Subject(s)
Antihypertensive Agents/adverse effects , Calcium Channel Blockers/adverse effects , Immunosuppressive Agents/adverse effects , Liver Transplantation , Mibefradil/adverse effects , Tacrolimus/adverse effects , Antihypertensive Agents/pharmacokinetics , Antihypertensive Agents/therapeutic use , Calcium Channel Blockers/pharmacokinetics , Calcium Channel Blockers/therapeutic use , Cytochrome P-450 Enzyme Inhibitors , Drug Interactions , Humans , Immunosuppressive Agents/pharmacokinetics , Immunosuppressive Agents/therapeutic use , Liver Transplantation/immunology , Male , Metabolic Clearance Rate/drug effects , Mibefradil/pharmacokinetics , Mibefradil/therapeutic use , Middle Aged , Tacrolimus/pharmacokinetics , Tacrolimus/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...